Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [11] Population pharmacokinetic (PK) analysis of lanreotide autogel/depot in the treatment of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs): Pooled analysis of four clinical trials.
    Buil-Bruna, Nuria
    Garrido, Maria Jesus
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Gomez-Panzani, Edda L.
    Troconiz, Inaki F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [12] Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours
    Phan, A.
    Caplin, M.
    Pavel, M.
    Cwikla, J.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wolin, E.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S460 - S460
  • [13] Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension
    Vinik, Aaron
    Fisher, George, Jr.
    Kunz, Pamela
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney
    Shaheen, Montaser
    Wolin, Edward
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [14] Lanreotide Depot/Autogel (LAN) Vs. Placebo (PBO) for Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs): Subgroup Analysis of the ELECT Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 10 - 11
  • [15] Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study
    Prasad, V
    Thanh, Truong X. M.
    Houchard, A.
    Bodei, L.
    NEUROENDOCRINOLOGY, 2017, 105 : 253 - 253
  • [16] Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
    Baudin, E.
    Horsch, D.
    Singh, S.
    Caplin, M. E.
    Ferone, D.
    Wolin, E. M.
    Capdevila, J.
    Buikhuisen, W. A.
    Raderer, M.
    Dansin, E.
    Grohe, C.
    Houchard, A.
    Thanh, X-M. Truong
    Reidy-Lagunes, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S906 - S906
  • [17] Lanreotide Autogel/Depot (LAN) in Patients With Advanced Bronchopulmonary (BP) Neuroendocrine Tumors (NETs): Results From the Phase 3 SPINET Study
    Reidy-Lagunes, Diane
    Horsch, Dieter
    Singh, Simron
    Caplin, Martyn E.
    Ferone, Diego
    Wolin, Edward M.
    Capdevila, Jaume
    Buikhuisen, Wieneke
    Raderer, Markus
    Dansin, Eric
    Grohe, Christian
    Houchard, Aude
    Truong-Thanh, Xuan-Mai
    Baudin, Eric
    PANCREAS, 2022, 51 (03) : E37 - E38
  • [18] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [19] Lanreotide Autogel/ Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
    Reidy-Lagunes, D.
    Kulke, M. H.
    Wolin, E. M.
    Singh, S.
    Ferone, D.
    Hoersch, D.
    Mirakhur, B.
    Hoffmanns, P.
    Houchard, A.
    Caplin, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2017, 105 : 209 - 209
  • [20] Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345